Imatinib mesylate in desmoplastic small round cell tumors

Rita De Sanctis, Alexia Bertuzzi, Gianni Bisogno, Modesto Carli, Andrea Ferrari, Alessandro Comandone, Armando Santoro

Research output: Contribution to journalArticlepeer-review


Aim: To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT). Patients & methods: From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate. Results: Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients. Conclusion: Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.

Original languageEnglish
Pages (from-to)1233-1237
Number of pages5
JournalFuture Oncology
Issue number14
Publication statusPublished - Jun 1 2017


  • c-KIT
  • desmoplastic small round cell tumor
  • imatinib
  • PDGF-Rα
  • PDGF-Rβ

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Imatinib mesylate in desmoplastic small round cell tumors'. Together they form a unique fingerprint.

Cite this